Archive - April 2025
Bristol Myers Squibb’s Cobenfy Falls Short in Phase III Trial as Add On Therapy for Schizophrenia
Industry Outlook 2025: The Impact of Politics on Pharma
Over half of U.S. counties have no system in place for monitoring air quality
Making Real-World Evidence Work for Medicare: What CMS’ Draft Guidance Gets Right and What Needs Work
Anti-Anxiety Drugs in Water Change Salmon Behavior, Study Finds
Where Does Rare Disease and Patient-Focus Fall into Commissioner Makary’s Priorities & the MAHA Platform for FDA? A New Ultrarare Approval Pathway & More
Roche to Invest $50 Billion in US Pharmaceuticals and Diagnostics
STAT+: Pharmalittle: We’re reading about Lilly strategy against compounders, Bristol’s antipsychotic, and more